tracking

Upcoming Events

Emstopa: Treating and Preventing Bleeding Complications in tPA Patients

Emstopa: Treating and Preventing Bleeding Complications in tPA Patients

Thursday, Jul 6 at 3:00 PM

Register Now

Clot busting, tPA-based drugs are often used to treat stroke, pulmonary embolism, myocardial infarction and other head traumas. And their use is on the rise -- according to a study sponsored by Massachusetts General Hospital, tPA usage increased from 43% to 77% between 2003 and 2011, and the trend has only continued from there.

However, tPA is not a miracle drug. In more than 5% of cases, tPA can lead to severe intracranial hemorrhaging and excessive brain bleeding that rapidly spirals out of control. In those cases, the mortality rate is 50%.

EmstoPA is a monoclonal antibody fragment that inhibits the activity of tPA in the body to improve these outcomes. When administered to patients experiencing brain bleeding as a result of tPA, it quickly reverses the complications and contributes to improved patient recovery.

ProteoSense: Making Foodborne Illness a Thing of the Past

ProteoSense: Making Foodborne Illness a Thing of the Past

Thursday, Jun 29 at 3:00 PM

Register Now

The risk of foodborne illness isn’t just for the history books, and thanks to recent cases such as those that struck national brands like Chipotle, Chi-Chi’s, Peter Pan Peanut Butter and others in the last 10 years, we are all more aware of that fact now more than ever.

ProteoSense understands this need and has been commercializing a new solid-state biosensor technology for food safety testing. ProteoSense’s RapidScan technology is a high-sensitivity, handheld system that can detect foodborne pathogens in just minutes without incubation, reducing the overall total test time and allowing for on-the-fly testing in the field or the factory.

Entac Medical: Predicting Medical Conditions With Sound Waves

Entac Medical: Predicting Medical Conditions With Sound Waves

Thursday, Jun 22 at 3:00 PM

Register Now

Gastrointestinal impairment, particularly postoperative ileus, affects hundreds of thousands of surgical patients in the U.S. every year, striking them with nausea, vomiting, and abdominal pain in the days after surgery. As many as 25% of all colorectal surgery patients experience these symptoms. The inability to predict patients at risk often unnecessarily increases hospital stays by 4-6 days and causes readmission rates in excess of 20%, making this one of the most prevalent conditions for readmissions of surgical patients. The financial impact of over-utilization of hospital resources is estimated to be $10-$15 billion per year in the U.S.

Entac Medical is developing noninvasive devices for the prediction and diagnosis of postoperative ileus and other medical conditions, leveraging audio spectral analysis. Its first device, PrevisEA, is affixed to the abdomen and uses a microphone to detect biological signals that are highly correlated with gastrointestinal impairment, with up to 95% accuracy.

View Past Webinars

Hazel Technologies: Improving Efficiency and Reducing Waste in the Produce Supply Chain

Hazel Technologies: Improving Efficiency and Reducing Waste in the Produce Supply Chain

Jun 15, 2017

Watch Replay

Over 30% of produce harvested is never consumed.

This means that all of the resources: time, energy, money, and water put into cultivating this produce is also wasted. This produce waste does not occur at one single point in the supply chain.

At Hazel Technologies, we develop new solutions to mitigate this waste in order to improve the efficiency of our fresh produce supply chain.

OnFarm: Turning Data into Better Farming

OnFarm: Turning Data into Better Farming

Jun 8, 2017

Watch Replay

Every major industry has been digitized except Agriculture This is happening now and data is becoming the most valuable asset on the farm.

OnFarm is a software-as-a-service company that offers a range of farm hardware technologies. The company’s products offer customized dashboards, data management, intuitive displays to help transform data into decisions, advanced charting, enterprise-wide scheduling, phone and email alerts, maps, private communication solutions, and more.

Geneoscopy: Revolutionizing Colorectal Cancer Screening

Geneoscopy: Revolutionizing Colorectal Cancer Screening

Jun 1, 2017

Watch Replay

Colorectal cancer (CRC) is the 2nd leading cause of cancer-related deaths in the U.S., resulting in over 50,000 deaths annually. CRC’s high mortality rate is due, in part, to flaws in existing methodologies to screen for the disease. Colonoscopies are expensive, time-consuming and uncomfortable, so patients avoid them, and noninvasive alternatives are not accurate enough to serve as a reliable replacement.

Geneoscopy has created a series of patent-pending methods that allow for the isolation and preservation of biomarkers in stool samples. Geneoscopy has used this technique to develop a screening test for the detection of colorectal neoplasia-associated RNA biomarkers. The Geneoscopy test has the potential to lower mortality rates associated with CRC by increasing screening compliance and allowing for earlier detection of the disease.

Conservis: Meeting the Global Demand for Agriculture

Conservis: Meeting the Global Demand for Agriculture

May 25, 2017

Watch Replay

Conservis is dedicated to helping growers and producers meet the growing, global demand for agricultural products. Our trusted farm management software solutions help businesses make better decisions, lead more effective operations, share information with stakeholders, improve traceability and implement sustainable practices. As an independent partner, we keep evolving to meet new challenges and make farm-level data more actionable season after season. We are trusted to manage over $8 billion in land, equipment and crop assets, including permanent and row crops, at all stages of production. We serve growers in the US, Canada, Australia and Argentina.

AdKiosks: Transforming the Digital Advertising Industry

AdKiosks: Transforming the Digital Advertising Industry

May 18, 2017

Watch Replay

Display advertising has become a costly proposition for marketers, limited by space and the fact that traditional banner ads and site placements can only display one advertisement at a time. With potential buyer interest narrowed to a single item, the click potential of each ad is limited, which also limits its revenue potential. Still, the display advertising market in the U.S. alone is projected to reach $41.7 billion in 2017 and $64.5 billion in 2021, exceeding ad-search for the first time.

AdKiosks is working to improve digital advertising for publishers and marketers alike, with a digital ad platform that enables advertisers to display unlimited products from a single ad space. Moreover, The company’s technology also enables potential buyers to transact through the ad platform itself without ever leaving an ad publisher's website, increasing revenue upside for both parties.

Euclises: Battling the Deadliest Cancers with Immunotherapy

Euclises: Battling the Deadliest Cancers with Immunotherapy

May 4, 2017

Watch Replay

Colorectal, non-small cell lung and pancreatic cancers are some of the deadliest cancers the medical community faces today, combining to kill nearly 350,000 people each year in the U.S. In fact, colorectal cancer alone is the third-most-commonly diagnosed cancer in the U.S. and globally, with five-year survival rates of around 65%. Euclises is developing COX-2 inhibitors designed for use in combination with immunotherapy treatments, to aid the body’s natural immune cells in killing cancer cells. Euclises founder, Dr. John Talley is best known as the key scientist behind the blockbuster anti-inflammatory COX-2 inhibitor Celebrex® and is acknowledged as one of the top 15 most influential people in the global pharmaceutical industry.

Satisfi: Bringing the Human Touch to Artificial Intelligence

Satisfi: Bringing the Human Touch to Artificial Intelligence

Apr 27, 2017

Watch Replay

Technology is transforming our world, but there is no getting over the fact that chatbots, digital assistants and other AI wonders are lacking the intuition and adaptability of the human touch. Based in New York City, Satisfi Labs is dedicated to closing this gap, with intelligent products that combine the speed and accuracy of automation with the personality and flexibility of a live person.

The company’s unique, location-based mobile tools enable AI interactions that have, until now, been the stuff of science fiction, helping companies learn more than ever about their customers while at the same time delivering unmatched customer service. This type of customer focused Artificial Intelligence is helping businesses drive sales, improve service and increase customer retention in ways that have never before been possible.

Gila Therapeutics: A Novel Approach to Tackling Obesity

Gila Therapeutics: A Novel Approach to Tackling Obesity

Apr 20, 2017

Watch Replay

Obesity is one of the leading causes of health issues that collectively cost the US healthcare system $150B annually. Among Americans, 120M are overweight, 108M annually make multiple attempts to lose weight, and $20B is spent annually on weight loss, yet less than 1% are successful. Existing treatments have had little impact on this epidemic due to poor efficacy and/or numerous safety issues.

Gila Therapeutics is developing a treatment for obesity using naturally occurring hormones known to aid in reducing calories consumed leading to weight loss. By employing a novel, intra–oral application method that targets a recently discovered neural pathway between the tongue and the brain, the treatment is expected to greatly improve results by avoiding previously experienced negative side effects. Gila is developing formulations to be applied to the tongue five minutes prior to meals to directly stimulate the brain’s satiety centers to reduce food intake. These formulations delivered via the novel intra-oral application method have successfully resulted in caloric intake reduction in animal models without any adverse reactions.

Holganix: Environmentally Sustainable Agriculture Technology: Finding an answer to the increasing consumer concern over use of GMOs

Holganix: Environmentally Sustainable Agriculture Technology: Finding an answer to the increasing consumer concern over use of GMOs

Apr 13, 2017

Watch Replay

Food demand is expected to double by 2050, yet the use of genetically modified organisms (GMO) to increase yield is meeting with consumer revolt.  Demand for organic food is growing significantly faster than the acreage to produce it, leading to unsustainable price increases.  The use of water, an already scarce resource, fertilizers, herbicides, pesticides, and fungicides is increasingly being limited by regulation. Holganix’ organic plant probiotic reduces the need for herbicides, pesticides, fungicides, fertilizer and water while simultaneously increasing the vibrancy and yield of the plant. Much like human probiotics found in yogurt promote digestive health, Holganix plant probiotics make soils and plants healthier, more resilient, and more productive. The Company’s initial commercial success has been achieved through retail and wholesale distribution to the turf, lawn, and golf   course industries, including over 15 of the top 100 golf courses (e.g., Muirfield and Torrey Pines) and over 10 professional athletic organizations (e.g., St Louis Cardinals, Chicago Cubs, Miami Dolphins). To capitalize on the larger size of the market and the rapidly growing trends towards environmental sustainability and healthy, organic food, the Company has extended its operations for use in the agriculture industry.

Agrible: Bringing Predictive Analytics to the Farm

Agrible: Bringing Predictive Analytics to the Farm

Apr 6, 2017

Watch Replay

Predictive analytics are changing the way that food is produced, helping to make farmers more efficient, suppliers more reliable and the entire value chain more sustainable. Based in Champaign, Illinois, Agrible is developing a crop growth model that provides highly accurate field-by-field predictive analytics, delivering field-level data to help farmers and all stakeholders deliver on their promises. What’s more, its output analytics are helping producers and other partners, from the field to the shelf, better understand each other and work together, forwarding the mission of advanced, data-driven agriculture.

Zumbro Discovery: Novel Treatments for Resistant Hypertension

Zumbro Discovery: Novel Treatments for Resistant Hypertension

Mar 30, 2017

Watch Replay

High blood pressure affects more than 67 million Americans, according to the CDC, and as many as nine million of those suffer from resistant hypertension, a type that currently has no approved drug treatments. Zumbro Discovery is a clinical-stage biotech company that is developing novel atrial natriuretic peptides for the treatment of resistant hypertension. ZD100, the company’s lead compound, is a patent-protected mutant atrial natriuretic peptide that targets the GC-A receptor and is based on decades of research by the company’s co-founders at the Mayo Clinic. “Novel Treatments for Resistant Hypertension” will cover Zumbro’s work in this area as well as the science behind its treatments.

ProteoSense: Making Foodborne Illness a Thing of the Past

ProteoSense: Making Foodborne Illness a Thing of the Past

Mar 23, 2017

Watch Replay

The risk of foodborne illness isn’t just for the history books, and thanks to recent cases such as those that struck national brands like Chipotle, Chi-Chi’s, Peter Pan Peanut Butter and others in the last 10 years, we are all more aware of that fact now more than ever.

ProteoSense understands this need and has been commercializing a new solid-state biosensor technology for food safety testing. ProteoSense’s RapidScan technology is a high-sensitivity, handheld system that can detect foodborne pathogens in just minutes without incubation, reducing the overall total test time and allowing for on-the-fly testing in the field or the factory.

PopBookings: Disrupting the Temporary Staffing Industry

PopBookings: Disrupting the Temporary Staffing Industry

Mar 16, 2017

Watch Replay

The U.S. labor market is changing, with more and more jobs becoming temporary or on-demand. According to the Bureau of Labor Statistics, more than 27 million people are currently employed on a part-time basis, with temporary placements representing the fastest-growing segment of the employment economy. This is the “gig economy”

PopBookings is streamlining the entire relationship between temporary jobs and the people that work them, including sourcing, vetting, managing, and payments. The company’s mobile and web applications connect agencies and the events they represent with the right talent, consolidating the hiring process for staffing agencies by combining booking, logging, paying, and communicating into one platform.

Cofactor Genomics: Using RNA to Diagnose Disease

Cofactor Genomics: Using RNA to Diagnose Disease

Mar 9, 2017

Watch Replay

Reading a patient’s DNA informs someone about a probability of someday contracting the disease, but says little about their current state of health. This is because our DNA remains largely unchanged throughout our life. RNA, on the other hand, is changing all the time in response to diet, exercise, infection, and disease. It serves as a barometer of health, reporting on what is happening in your body right at this instant. Our team of former Human Genome Project Scientists (who have worked together for 15 years) have developed technologies necessary to enable RNA’s use as a diagnostic.

Cofactor Genomics uses RNA to diagnose disease. Our RNA-based tests are enabling drug companies to develop new drugs and helping physicians make personalized medicine a reality.

Epharmix: Revolutionizing Provider-Patient Communication With Mobile Technology

Epharmix: Revolutionizing Provider-Patient Communication With Mobile Technology

Mar 2, 2017

Watch Replay

As of today, 99% of all healthcare delivery in this country happens outside of the office, not when people are face to face with their doctor. Healthcare systems are starting to realize this, and they are now staffing rooms full of nurses to monitor the highest risk patients no matter where they are located. This is a trend that, with support from the right technology, has the potential to dramatically improve patient satisfaction, patient health and business health for providers all at the same time. Epharmix is developing new tools to enable effortless, seamless patient monitoring, using automated phone calls and text messages to deliver condition-specific information and help increase access to outcomes for any patient. The unobtrusive system helps care teams improve outcomes with just a phone number, using mobile technology to collect patient data while they go about their daily lives, improving patients results while simultaneously reducing workloads for providers.

FairWords: Using AI in Digital Communication to Strengthen Compliance in Regulated Industries

FairWords: Using AI in Digital Communication to Strengthen Compliance in Regulated Industries

Feb 23, 2017

Watch Replay

Enterprise compliance is growing increasingly complex. With 131 million knowledge workers in the United States using multiple devices, there are mountains of digital communications that represent potential legal, regulatory, and/or ethical liabilities for today’s enterprise. By 2018, business email alone will account for over 139.4 billion emails per day or 140 emails per person per day. Companies in many regulated industries (e.g., financial services) are forced to review and archive employee communication to prove legal and regulatory compliance if and when audited. FairWords monitors and archives all digital employee communications on authorized company devices using artificial intelligence (AI) to ensure compliance in regulated industries. Its platform provides enterprises the ability to monitor and control all electronic and voice communications, at the point of origination, or in archives, and identify items that present a regulatory risk to the organization. And, it does so faster, cheaper and with greater functionality than current solutions.

Better Weekdays: College Recruiting Simplified

Better Weekdays: College Recruiting Simplified

Feb 16, 2017

Watch Replay

Recent graduates account for over half of all entry level hires, yet corporations struggle to effectively recruit millennials.  Traditional recruiting methods, such as careers fairs and job boards, are ineffective and misaligned with how millennials discover products, services, and people.

Better Weekdays, Inc. reduces friction in the job search and campus recruiting process for students, colleges, and employers. BW’s interactive, mobile enabled, marketing and communications platform provides tools and services, including self/career assessment and personalized job-matching, that allow: 1) students to discover relevant job opportunities aligned with their job preferences and corporate culture fit; 2) corporations to market the best content about a relevant job to the right student at the right time; and 3) university career centers to leverage data and analytics to engage students, alumni, and employers by being more relevant, more helpful, more personalized and less interruptive than traditional career center operations, which improves its graduates job outcomes.  Focused job seeker engagement allows recruiting teams to be more efficient and effective with their on-campus recruiting efforts, increasing quality of hire while reducing time to fill positions and cost per hire.  

Gila Therapeutics: A Novel Approach to Tackling Obesity

Gila Therapeutics: A Novel Approach to Tackling Obesity

Feb 9, 2017

Watch Replay

Obesity is one of the leading causes of health issues that collectively cost the US healthcare system $150B annually. Among Americans, 120M are overweight, 108M annually make multiple attempts to lose weight, and $20B is spent annually on weight loss, yet less than 1% are successful. Existing treatments have had little impact on this epidemic due to poor efficacy and/or numerous safety issues.

Gila Therapeutics is developing a treatment for obesity using naturally occurring hormones known to aid in reducing calories consumed leading to weight loss. By employing a novel, intra–oral application method that targets a recently discovered neural pathway between the tongue and the brain, the treatment is expected to greatly improve results by avoiding previously experienced negative side effects. Gila is developing formulations to be applied to the tongue five minutes prior to meals to directly stimulate the brain’s satiety centers to reduce food intake. These formulations delivered via the novel intra-oral application method have successfully resulted in caloric intake reduction in animal models without any adverse reactions.

Benson Hill: Innovation in Agriculture: plant biology, data analytics and cloud computing

Benson Hill: Innovation in Agriculture: plant biology, data analytics and cloud computing

Feb 2, 2017

Watch Replay

The global population is booming, diets are shifting and urbanization is rising. Never has so much been asked of agriculture to meet the needs of our society. Never have the external risks to agricultural advancement been greater, whether from a changing climate, limited natural resources,  concerns over chemical inputs, protests over GMO, industry consolidation, or reduced choice in the marketplace. New innovation and new innovators are needed to advance agriculture for people and our planet. The emerging era of Cloud Biology, the combination of plant biology, big data analytics and cloud computing, will enable innovation in agriculture throughout the value chain. Our speaker Benson Hill is pioneering the use of Cloud Biology and delivering on its promise to solve some of the world’s greatest agricultural challenges.

Immunophotonics: Creating a Cancer Vaccine with ImmunoTherapy

Immunophotonics: Creating a Cancer Vaccine with ImmunoTherapy

Jan 26, 2017

Watch Replay

Frequently in later stage cancers,  cancer cells metastasize or break away from the original tumor and spread to other parts of the body. Metastatic cancer patients are limited in their access to potential treatments. Immunophotonics is a biotech company developing a proprietary drug for use in a therapeutic cancer vaccine. This novel immunotherapy begins with a two injection procedure into any one accessible tumor, intended to liberate and utilize the patient’s tumor antigens to generate a systemic antitumor immune response.  Phase 1/2 in-human results with Stage 4 metastatic breast cancer patients have shown efficacy in treating not only the primary tumor, but metastatic tumors as well.

Hatchbuck: The New World of Marketing Automation

Hatchbuck: The New World of Marketing Automation

Jan 19, 2017

Watch Replay

What does every business need? Customers! Every small to midsize business struggles with being able to follow up with all of their prospects and customers, and drive new business with limited staff, time and resources. There’s currently a large market gap for Marketing Automation tools for small to midsized companies. Hatchbuck fills that gap and offers an all-in-one solution that combines CRM, Email Marketing and Marketing Automation. What Hatchbuck does really well is identify the needs and interests of each prospect and automatically sends the right message to the right person at the right time. Personalization and nurturing dramatically boosts overall engagement, ultimately enabling a business to convert more prospects into customers and increase customer retention rates.

Holganix: Environmentally Sustainable Agriculture Technology: Finding an answer to the increasing consumer concern over use of GMOs

Holganix: Environmentally Sustainable Agriculture Technology: Finding an answer to the increasing consumer concern over use of GMOs

Jan 12, 2017

Watch Replay

Food demand is expected to double by 2050, yet the use of genetically modified organisms (GMO) to increase yield is meeting with consumer revolt.  Demand for organic food is growing significantly faster than the acreage to produce it, leading to unsustainable price increases.  The use of water, an already scarce resource, fertilizers, herbicides, pesticides, and fungicides is increasingly being limited by regulation. Holganix’ organic plant probiotic reduces the need for herbicides, pesticides, fungicides, fertilizer and water while simultaneously increasing the vibrancy and yield of the plant. Much like human probiotics found in yogurt promote digestive health, Holganix plant probiotics make soils and plants healthier, more resilient, and more productive. The Company’s initial commercial success has been achieved through retail and wholesale distribution to the turf, lawn, and golf   course industries, including over 15 of the top 100 golf courses (e.g., Muirfield and Torrey Pines) and over 10 professional athletic organizations (e.g., St Louis Cardinals, Chicago Cubs, Miami Dolphins). To capitalize on the larger size of the market and the rapidly growing trends towards environmental sustainability and healthy, organic food, the Company has extended its operations for use in the agriculture industry.

Euclises: Battling the Deadliest Cancers with Immunotherapy

Euclises: Battling the Deadliest Cancers with Immunotherapy

Jan 5, 2017

Watch Replay

Colorectal, non-small cell lung and pancreatic cancers are some of the deadliest cancers the medical community faces today, combining to kill nearly 350,000 people each year in the U.S. In fact, colorectal cancer alone is the third-most-commonly diagnosed cancer in the U.S. and globally, with five-year survival rates of around 65%. Euclises is developing COX-2 inhibitors designed for use in combination with immunotherapy treatments, to aid the body’s natural immune cells in killing cancer cells. Euclises founder, Dr. John Talley is best known as the key scientist behind the blockbuster anti-inflammatory COX-2 inhibitor Celebrex® and is acknowledged as one of the top 15 most influential people in the global pharmaceutical industry.

Neuros Medical: Managing Chronic Pain Without the Use of Narcotics

Neuros Medical: Managing Chronic Pain Without the Use of Narcotics

Dec 8, 2016

Watch Replay

Chronic pain affects over 100 million Americans and can be caused by everything from spine disorders, to diabetes, to residual limb pain following amputation. Chronic migraine pain affects as many as 30 million patients in the U.S. alone, and another 500,000 deal with chronic post-surgical pain every day. Current treatments predominantly rely on local anesthetic injection, predominantly lidocaine, or other pain medications, all of which are limited in duration and efficacy and bring other complications including addiction. Neuros Medical’s breakthrough pain management technology delivers high-frequency stimulation to sensory nerves in the peripheral nervous system to block pain signals. The system consists of an electrode placed around a peripheral nerve and powered by a pacemaker-sized generator. Pilot studies among patients with residual limb pain have shown significant pain reductions, leading more than half of study patients to discontinue their pain medication.

Bractlet: How REITs and Corporations are using Energy Savings to increase Property Values

Bractlet: How REITs and Corporations are using Energy Savings to increase Property Values

Nov 17, 2016

Watch Replay

Across this country, innovative new companies lead change and growth in areas like healthcare, agriculture, and energy. Every Thursday at 3PM Central, iSelect hosts a webinar highlighting one of these companies. Our next episode on Nov 17th, is about Bractlet, an Austin based software company focused on helping commercial buildings become more valuable by implementing energy efficient products and processes.

Did you know real estate operators can now reduce energy spending, improve maintenance and increase the value of their commercial properties, all with a quick payback?

Bractlet’s novel software solution harnesses cloud computing and automated data collection to dramatically reduce energy waste for commercial building owners. Bractlet works with large building portfolio owners in the commercial office building, hospital and data center sectors to help them implement the best and most enduring payback opportunities for energy efficient products and processes.
If you own commercial real estate or want to invest in smart emerging companies, you should hear the Bractlet story.

iSelect keeps a constant watch on emerging opportunities. If you are an investor, iSelect vets these companies, providing you easy access to invest before these companies are widely-known. If you own commercial real estate, iSelect provides you early access to cutting edge solutions that give you competitive advantage.

Sign up to watch the webinar on Nov 17th, at 3pm. If you can’t attend, sign up and you will get a link to the saved broadcast to view any time.

Read more: Clean, Cheap and Profitable: Boosting Real Estate Valuations the Easy Way -https://goo.gl/C10lpk36135aee55f8#.ezbpsebyh